Oncolytic Virus Cancer Therapy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight's, "Oncolytic Virus Cancer Therapy Pipeline Insight" report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Oncolytic Virus Cancer Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Oncolytic Virus Cancer Therapy Pipeline Report to explore emerging therapies, key Oncolytic Virus Cancer Therapy Companies, and future Oncolytic Virus Cancer Therapy treatment landscapes @ Oncolytic Virus Cancer Therapy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report

* In February 2025:- Lokon Pharma AB:- The purpose of this study is to see if LOAd703 (an oncolytic adenovirus) can be safely given to patients with pancreatic cancer. The study will also evaluate whether or not intratumoral injection of LOAd703 will support current standard of care treatment to reduce the size of the tumor and improve survival of the patients.
* DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
* The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
* Promising Oncolytic Virus Cancer Therapy Therapies such as ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda, pembrolizumab, TILT-123, and others.

Discover how the Oncolytic Virus Cancer Therapy treatment paradigm is evolving. Access DelveInsight's in-depth Oncolytic Virus Cancer Therapy Pipeline Analysis for a closer look at promising breakthroughs @ Oncolytic Virus Cancer Therapy Clinical Trials and Studies [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Oncolytic Virus Cancer Therapy Emerging Drugs Profile

* Olvi-Vec: Genelux Corporation

Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

* CAN-2409: Candel Therapeutics

CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer.

* CG0070: CG Oncology

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer.

* Pelareorep: Oncolytics Biotech

Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer.

* ParvOryx: Oryx GmbH

ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer.

* SND005: Jiangsu Sinorda Biomedicine

SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients.

* VCN-01: VCN Biosciences

VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.

The Oncolytic Virus Cancer Therapy pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
* Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.

Get a detailed analysis of the latest innovations in the Oncolytic Virus Cancer Therapy pipeline. Explore DelveInsight's expert-driven report today! @ Oncolytic Virus Cancer Therapy Unmet Needs [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Oncolytic Virus Cancer Therapy Companies

Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intranasal
* Intravenous
* Oral
* Oral/Intravenous
* Parenteral
* Subcutaneous
* Subcutaneous/Intramuscular

Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as

* Oncolytic Viruse

Download DelveInsight's latest report to gain strategic insights into upcoming Oncolytic Virus Cancer Therapy Therapies and key Oncolytic Virus Cancer Therapy Developments @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Oncolytic Virus Cancer Therapy Pipeline Report

* Coverage- Global
* Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Turnstone Biologics, and others.
* Promising Oncolytic Virus Cancer Therapy Therapies- ONCOS-102, gemcitabine, VRT106, CG0070, Keytruda, pembrolizumab, TILT-123 , and others.
* Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Oncolytic Virus Cancer Therapy drug development? Find out in DelveInsight's exclusive Oncolytic Virus Cancer Therapy Pipeline Report-access it now! @ Oncolytic Virus Cancer Therapy Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/oncolytic-virus-cancer-therapy-pipeline-insight-2021?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Oncolytic Virus Cancer Therapy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Oncolytic Virus Cancer Therapy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Olvi-Vec: Genelux Corporation
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SND005: Jiangsu Sinorda Biomedicine
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* AloCelyvir: Orgenesis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* VCN-01: VCN Biosciences
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* SynOV 1.3: Beijing Syngentech
* Drug profiles in the detailed report.....
* Inactive Products
* Oncolytic Virus Cancer Therapy Key Companies
* Oncolytic Virus Cancer Therapy Key Products
* Oncolytic Virus Cancer Therapy- Unmet Needs
* Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
* Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
* Oncolytic Virus Cancer Therapy Analyst Views
* Oncolytic Virus Cancer Therapy Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oncolytic-virus-cancer-therapy-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.